Related Experiment Videos
Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial
Insights
Daily oral penicillin significantly reduced invasive Streptococcus pneumoniae infections in young children with sickle cell anemia. This crucial intervention lowers infection rates and prevents deaths, highlighting the importance of early screening and prophylaxis.
Area of Science:
- Pediatrics
- Infectious Diseases
- Hematology
Background:
- Children with sickle cell anemia (SCA) face a heightened risk of severe bacterial infections.
- Streptococcus pneumoniae is a primary pathogen causing life-threatening infections in this vulnerable population.
Purpose of the Study:
- To evaluate the efficacy of daily oral penicillin prophylaxis in preventing Streptococcus pneumoniae septicemia.
- To assess the impact of penicillin on morbidity and mortality in children under three with SCA.
Main Methods:
- A multicenter, randomized, double-blind, placebo-controlled trial.
- 125 mg of oral penicillin V potassium or placebo administered twice daily to children with SCA under three years old.
- Follow-up averaged 15 months, with the trial stopped early due to observed efficacy.
Main Results:
- An 84% reduction in the incidence of documented S. pneumoniae infections in the penicillin group compared to placebo (2/105 vs. 13/110).
- No deaths from pneumococcal septicemia occurred in the penicillin group, versus three deaths in the placebo group.
- The observed difference was statistically significant (P = 0.0025).
Conclusions:
- Routine screening for sickle cell hemoglobinopathy in newborns is recommended.
- Prophylactic oral penicillin therapy initiated by four months of age is crucial for reducing pneumococcal septicemia-related morbidity and mortality in children with SCA.
Abstract:
Children with sickle cell anemia have an increased susceptibility to bacterial infections, especially to those caused by Streptococcus pneumoniae. We therefore conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial to test whether the regular, daily administration of oral penicillin would reduce the incidence of documented septicemia due to S.pneumoniae in children with sickle cell anemia who were under the age of three years at the time of entry. The children were randomly assigned to receive either 125 mg of penicillin V potassium (105 children) or placebo (110 children) twice daily. The trial was terminated 8 months early, after an average of 15 months of follow-up, when an 84 percent reduction in the incidence of infection was observed in the group treated with penicillin, as compared with the group given placebo (13 of 110 patients vs. 2 of 105; P = 0.0025), with no deaths from pneumococcal septicemia occurring in the penicillin group but three deaths from the infection occurring in the placebo group. On the basis of these results, we conclude that children should be screened in the neonatal period for sickle cell hemoglobinopathy and that those with sickle cell anemia should receive prophylactic therapy with oral penicillin by four months of age to decrease the morbidity and mortality associated with pneumococcal septicemia.